Controlling drug-to-antibody ratio and scalable reactors are key to reliable antibody-drug conjugate manufacturing success.
Antibody-drug conjugates (ADCs) continue to reshape the oncology landscape by combining the target specificity of monoclonal antibodies (mAbs) with the potent cytotoxicity of small-molecule drugs.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results